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Proliferating cell nuclear antigen (PCNA) is an auxiliary protein of
DNA　 polymerase-∂ 　that　 is　synthesized　 during　 the　 late　 G1　 phase
through the S phase of cell proliferation. The expression of PCNA 
correlates strongly with cell proliferation. In the present study, 
employing NC-012, which is an anti-human PCNA monoclonal 
antibody, we performed immunohistochemical staining on specimens 
obtained from 71 new prostatic carcinoma patients by needle biopsy. 
We analyzed the results of PCNA immunoreactivity for correlation 
with the prognosis of the patients. The positive staining rate was 
0~11.4% for prostatic carcinoma, while it was 0~2.6% in 10 cases of 
benign prostatic hypertrophy. The PCNA-positive rate tended to be 
high in cases of moderately to poorly differentiated prostatic 
carcinoma, but it was not significant. With regard to the prognosis, it 
was found that the prognosis tended to be worse in the PCNA- positive 
cases compared with the PCNA-negative cases. Further, multivariate 
survival analysis of six parameters (i. e., the patient's age, histological 
grade, clinical stage, serum prostatic acid phosphatase, initial 
treatment and the PCNA-positive rate) revealed that the clinical stage, 
histological grade and the PCNA-positive rate were the first, second 
and third most significant prognostic parameters, respectively.
Introduction 
Not all prostatic carcinomas are clinically apparent, and 
even when recognized they do not all express the same 
biologic or malignant potential. This heterogeneity in the 
expression of prostatic carcinoma has been the source of 
much confusion and controversy, affecting the selection of 
appropriate therapy and the evaluation of results. There is a 
need to establish prognostic parameters which would iden-
tify those individuals who are unlikely to respond to con-
ventional treatment and would benefit from alternative 
therapies from the onset of clinical examination. Various 
histological grading and clinical staging systems for pros-
tatic carcinoma have been shown to have prognostic val-
ue. 1-3) 
 PCNA is a protein that is localized in the nucleus of 
proliferating cells. As an auxiliary protein of DNA poly-
merase- a , PCNA has a very close relationship with DNA 
synthesis. PCNA appears in the nucleus in the late G1 
phase immediately prior to the start of DNA synthesis, and 
its amount reaches a maximum in the S phase, when DNA 
synthesis begins." On the other hand, recently, with the
objective of judging the malignancy and prognosis of 
tumors, various studies have been carried out in the field of 
urology aimed at achieving determination of the presence 
of proliferating cells and their correlation with malignancy 
and the prognosis. Representative examples of the tech-
niques that have been applied are H3-thymidine, DNA-flow 
cytometry, bromodeoxyuridine, Ki-67 and argyrophilic 
nucleolar organizer regions." However, these technigies 
require the use of frozen sections of live tissues or fresh 
specimens, and they are thus especially unsuited for retro-
spective studies. In contrast, PCNA is an endogenous 
substance, and it is retained even after formalin fixation 
and paraffin embedding. Accordingly, the detection of 
PCNA is suited even for retrospective studies.
Materials and Methods 
Patients and Tissues 
We studied 71 new prostatic carcinoma patients, who had 
been so diagnosed between March 1980 and July 1990 at 
the Department of Urology of Nagasaki University Hos-
pital. Their average age at the time of diagnosis was 72.4 
years (range:50-90 years). Fifteen patients were in stage B 
(T2NoMo;TNM 198713'), 19 in stage C (T3,NoMo), and 37 in 
stage D (N1_3 or M1). As the initial treatment, a22 had 
received endocrine therapy; the majority were given estro-
gen or chlormadinone acetate, with or without bilateral 
orchiectomy, and the rest received a luteinizing hormone-
releasing hormone agonist. In addition, 54 received cyto-
toxic chemotherapy, the majority having been given cispla-
tin and adriamycin and/or 5-fluorouracil, while the balance 
was given other agents. 
  For our immunohistochemical study, formalin-fixed, 
paraffin-embedded tissue specimens of each patient's neo-
plastic prostatic glands were retrieved from the files of the 
Pathology Division of the Central Diagnostic Laboratory. 
All specimens were prepared from transperineal or trans-
rectal needle biopsies that had been conducted prior to 
treatment. All hematoxylin and eosin-stained sections of 
these cases were reviewed to assess the histological grade
according to Gleason's grading system For our controls, 
similarly fixed, paraffin-embedded tissue specimens of 
benign prostatic hypertrophy (BPH) were stained immuno-
histochemically, these latter tissue specimens have been 
obtained from patients with bladder cancer when they were 
undergoing total cystectomy 
Immunohistochemical Procedure 
Paraffin sections were stained immunohistochemically by a 
biotin-streptavidin method with horseradish peroxidase 
according to the following step-by-step procedure 
  1) deparaffinization in xylene-alcohol, 
  2) incubation in methanol containing 0 3% hydrogen 
peroxide for 20min to block endogenous peroxidase, 
 3) incubation in phosphate-buffered saline (PBS) (pH 
7 2) containing 2% bovine serum albumin and 10% goat 
serum for 60min to reduce nonspecific background stain-
ing, 
  4) incubation with a monoclonal PCNA antibody 
(NC-012, Novocastra Laboratories, Ltd, Newcastle upon 
Tyne, UK), at a dilution of 1 100 in PBS (pH 7 2) con-
taining 2% bovine serum albumin, overnight at 4 °C , 
  5) incubation with biotinylated goat anti-mouse IgG 
(Zymed Laboratories, Inc, San Francisco), 1 100 in PBS 
(pH 7 2) containing 2% bovine serum albumin for 60min, 
  6) incubation with peroxidase-conjugated streptavidin 
(Zymed Laboratories, Inc, San Francisco), 1 500 in PBS 
(pH 7 2) containing 2% bovine serum albumin for 30min, 
  7) subjection to a diaminobenzidine reaction with 
0 05% hydrogen peroxide for 5min, 
  8) counterstaining with hematoxylin, and, 
  9) mounting in glycerol 
  The slides were rinsed with PBS after step 2, and again 
rinsed with PBS after steps 4 through 6, and then rinsed 
with distilled water after steps 7 and 8 
Assessment of PCNA Staining 
Sections were counted at high power (x 200), and the 
nuclei of 1000 tumor cells were counted in each cases 
using an eyepiece graticule The PCNA index was calcu-
lated as the percentage of positive tumor cell nuclei The 
PCNA index of 0% was considered as negative staining 
and the index of more than 0 1% as positive staining 
Statistical Analysis 
Cancer-specific survival curves were calculated according 
to the Kaplan-Meier method and statistical significance was 
determined by the generalized Wilcoxon method In the 
cancer-specific survival analysis, deaths from causes unre-
lated to carcinoma of the prostate were treated as with-
drawals in the same manner as those lost to follow-up To 
establish which parameters might influence survival and to
estimate the extent of their impact, Cox's proportional 
hazards regression model was used 
 The possible prognostic parameters examined were the 
age, clinical stage, histological grade, serum prostatic acid 
phosphatase (PAP), PCNA positivity and the initial treat-
ment The correlations between the PCNA positivity and 
the other parameters were evaluated by the chi-square test
Results 
PCNA-immunolabeled nuclei were clearly and easily iden-
tified In both prostatic carcinoma and BPH specimens, 
immunostaining of PCNA was confined to the nuclei in the 
tissues, but it showed variable patterns Cribriform tumors 
often displayed more positivity than did other growth types 
of prostatic carcinoma (Fig 1) Of the 71 patients, 28 had a 
PCNA-negative tumor (39 4%) and 43 had a PCNA-
positive tumor (60 6%) The parameters and their cate-
gories studied by multivariate analysis are shown in Table 
1 The correlation between the PCNA immunoreactivity
Fig. 1. Immunohistochemical distribution of PCNA in the section 
of prostatic carcinoma Darkly stained nuclei are positive for 
PCNA A Area of prostatic tumor with a cnbnform pattern of 
growth x 200 B Area of prostatic tumor with a poorly differ-
entiated adenocarcinoma X 200
and the other parameters shown in Table 1 was evaluated 
by the chi-square test. As a result, the PCNA immuno-
reactivity showed no significant correlation with the histo-
logical grade or with the other four parameters, i. e., the 
age, clinical stage, serum PAP, and the initial treatment 
(Table 2). However, as Table 3 shows, the percentage of 
stained nuclei in well-, moderately- and poorly- differ-
entiated adenocarcinomas were 0.35 ± 0.42% (10 cases), 
1.88 -!- 2.88% (31 cases), 1.22 ± 2.36% (30 cases), 
respectively. Thus, the PCNA positivity was much higher 
in moderately- and poorly-differentiated tumors than in 
well-differentiated tumors. 
 The percentage of stained cells in the BPH specimens 
ranged from 0 to 2.6%, and eight of 10 cases stained 
negatively for PCNA (Fig. 2).
Table 3. Relationship of the histological grade to the PCNA 
       positivity
        Histological grade PCNA positivity                                     average (%)
Well differentiated adenocarcinoma 0.35 ± 0.42# 
Moderately differentiated adenocarcinoma 1.88 ± 2.88 
Poorly differentiated adenocarcinoma 1.22 ± 2.36 
Standard deviation.
Table 1. Six parameters and thier categories studied in Cox's 
        regression model
   Parameter Category 
                 1 2 3 
                     < 70 >_ 70 A
ge (27) # (44) 
Clinical stage B C D               (15) (19) (37)
Histological grade (10) (32) (33) 
Serum PAP Not elevated Elevated               (25) (46) 
PCNA Negative Positive 
immunoreactivity (28) (43) 
Initial treatment Chemo-endocrine Endocrine               (45) (26) 
'Number of patients .
Fig. 2. Immunohistochemical staining of PCNA in the section of 
BPH X 200.
Table 2. Correlation between the PCNA immunostaining score 
        and other parameters
                  PCNA immunoreactivity Chi-square 
                   Negative Positive test 
Age (yrs) 
  < 70 10 17 NS' 
  >_ 70 18 26 
Clinical stage 
  B 6 9 NS 
 C 10 9 
  D 12 25 
Histological grade 
  1 4 6 NS 
 2 11 21 
 3 13 16 
Serum PNA 
  Not elevated 11 14 NS 
  Elevated 17 29 
Initial treatment 
  Chemo-endocrine 16 29 NS 
  Endocrine 12 14 
Not statistical significance.
  Of the 71 prostatic carcinoma patients studied, 26 died 
due to their prostatic carcinoma. The cancer-specific sur-
vival curves, calculated according to the difference in the 
PCNA immunoreactivity, is shown in Fig. 3. The patients 
in the PCNA-positive group seemed to have a slightly 
worse prognosis than those in the PCNA-negative group, 
but this was not significant. 
 Table 4 shows the results of the multivariate analysis. 
The clinical stage (p = 0.002) and the histological grade (p 
= 0.01) were found to have a significant effect on the 
cancer-specific survival. Although the PCNA immuno-
Fig. 3. Cancer-specific survival curves according to the PCNA 
immunoreactivity.
Table 4. Multivariate analysis of possible prognotic parameters in Cox's regression model for patients with prostatic carcinoma
       Parameter Regression coefficient Standard error t value` P value 
 Age (yrs) 0.405 0.517 0.784 0.44 
 Clinical stage 1.315 0.405 3.245 0.002 
 Histological grade 1.012 0.392 2.582 0.01 
 Serum PAP -0.029 0.528 -0.054 0.96 
 PCNA immunoreactivity 0.669 0.522 1.282 0.20 
 Initial treatment -0.143 0.492 -0.291 0.77 
'
t = Regression coefficient / standard error.
reactivity (p = 0.2) was the third most significant prog-
nostic parameter, it failed to reach statistical significance.
Discussion 
Using the immunohistochemical staining method for 
PCNA, studies were carried out with regard to various 
kinds of malignant tumors to elucidate the relationships 
between their stage, grade, prognosis and their cell prolif-
eration. Louis et al. reported that, using fresh frozen speci-
mens of brain tumors, detection of PCNA expression was 
inferior to the Ki-67 technique for judging cell prolif-
eration. However, they demonstrated the usefulness of the 
PCNA immunohistochemical staining method since it can 
employ even paraffin-embedded specimens, and they also 
showed that the positive rate for PCNA expression in-
creases in direct proportion to the histological grade of the 
malignancy."' Woods et al."' investigated gastrointestinal 
lymphoma cases and found that PCNA expression corre-
lated well with the histological grade. They demonstrated 
that the prognosis became worse as the positive rate for 
PCNA expression increased, and the findings for PCNA 
immunoreactivity correlated well with the findings of DNA 
flow cytometry. Yu et al."' reported that PCNA expression 
correlated well with the histological grade in cases of 
hemangiopericytoma, and that there was a tendency for the 
prognosis to become worse as the positive rate for PCNA 
expression increased. Jain et al."' studied gastric carcinoma 
and reported that PCNA expression showed almost no 
correlation with the histological grade, clinical stage, lymph 
node metastasis, etc., but they found that patients with a 
high PCNA index seemed to have a slightly worse prog-
nosis. 
  Harper et al. 18' reported on their studies of PCNA expres-
sion in prostatic carcinoma. Using the PC-10 monoclonal 
antibody, they performed immunohistochemical staining on 
specimens from 102 cases of prostatic cacinoma and 20 
cases of BPH, and they demonstrated a PCNA index of 
1%-58% for prostatic carcinoma and an index of 0%-10% 
for BPH. In our present study employing the NC-012 
monoclonal antibody, we showed slightly lower ranges for 
the PCNA index: 0%-11.4% for 71 cases of prostatic 
carcinoma and 0%-2.6% for 10 cases of BPH.
  In addition, Harper and colleagues referred to the rela-
tionships between the PCNA index and the histological 
grade, clinical stage, metastatic status and age, and they 
reported a significant correlation between the PCNA index 
and the histological grade. They reported that there were no 
correlations between the PCNA index and the other param-
eters. In our study, although the PCNA index showed a 
tendency to be high in cases of moderately to poorly 
differentiated malignancies, there was no statistical signif-
icance. Furthermore, no significant correlation was noted 
between the PCNA index and the other parameters, i. e., 
the clinical stage, age, histological grade, serum PAP or 
initial treatment. 
  Moreover, Harper investigated the relationship between 
the PCNA index and the prognosis in 65 cases of prostatic 
carcinoma, and they reported that the prognosis was signif-
icantly (p < 0.04) better in the patient group having a 
PCNA index of 10% or higher compared with the patient 
group having an index of less than 10%. In our study, 
although the difference was not statistically significant (p = 
0.2), we found that the prognosis tended to be worse in the 
patient group that stained positively for PCNA in compar-
ison with the PCNA-negative group. 
 This discrepancy in the PCNA immunoreactive distri-
bution findings may have been caused by several factors. 
The difference in the monoclonal antibodies employed may 
be the primary reason. Second, the type of specimens 
evaluated was different. That is, in the Harper study, the 
specimens were obtained by transurethral resection (TUR), 
whereas we obtained our specimens by needle biopsy. 
Therefore, since a biopsy specimen or a TUR specimen 
does not always reflect the entirety of a tumor, a bias may 
have occurred in the tissue sampling. The third and final 
possible reason is the difference in tissue fixation; previous 
studies have indicated that PCNA is both heat and formal-
dehyde sensitive."' The method of collection of specimens, 
the handling of specimens until the time of fixation, the 
fixation procedure, and the time passed from fixation until 
staining may be factors that influence the results of PCNA 
immunohistochemical staining. In the present study, in fact, 
specimens that had been fixed more than 10 years earlier 
showed a tendency to have a lower rate of positive staining 
for PCNA than specimens fixed less than 10 years earlier. 
 Generally, the prognosis for patients with prostatic carci-
noma depends on the histological grade and clinical stage. 
In the present study, application of multivariate analysis to 
the six parameters of age, histological grade, clinical stage, 
serum PAP, the initial treatment and the PCNA immuno-
reactivity indicated the clinical stage to be the most impor-
tant prognostic parameter, followed by the histological 
grade. The PCNA immunoreactivity was demonstrated to 
be the third most statistically significant prognostic factor. 
  In conclusion, our study demonstrated that PCNA immu-
nohistochemical staining is easy to perform on routinely-
processed materials and permits retrospective studies. We 
also elucidated that the PCNA index shows a relationship 
with the histological grade. We surmise that positive PCNA 
immunoreactivity may be useful in clinical practice for 
identifying prostatic carcinoma patients with a poor prog-
nosis.
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